XOMA Royalty (XOMA) Company Report

XOMA Royalty Corporation announced an agreement to acquire Generation Bio Co. for a cash price of $4.2913 per share at closing, plus one non-transferable contingent value right (CVR) per share.
The CVR entitles Generation Bio stockholders to potential payments including 100% of net cash at closing exceeding $29 million, a share of proceeds from Generation Bio's existing license agreement with Moderna (up to 90%), and a share of payments from the out-license or sale of Generation Bio's ctLNP delivery platform (up to 70%).
Generation Bio's board of directors unanimously approved the Merger Agreement, and stockholders representing approximately 15% of Generation Bio common stock have signed support agreements to tender their shares.
The acquisition is expected to close in February 2026.

Dec 15, 2025, 10:00 PM

XOMA Royalty Completes Acquisition of Mural Oncology

XOMA

M&A

Delisting/Listing Issues

Takeover Bid

XOMA Royalty Corporation successfully completed its acquisition of Mural Oncology plc on December 5, 2025.
Mural shareholders received $2.035 in cash per share as consideration for the acquisition.
All of Mural's shares will cease trading on Nasdaq and will be delisted and deregistered under the Securities Exchange Act of 1934 on December 5, 2025.

Dec 5, 2025, 2:15 PM

XOMA Royalty Reports Q3 and Year-to-Date 2025 Financial Results, Highlights Acquisitions and Pipeline Progress

XOMA

Earnings

M&A

Share Buyback

XOMA Royalty reported $9.4 million in income and revenue for Q3 2025 and $38.4 million year-to-date 2025, with net income of $14.051 million for Q3 2025 and $25.609 million year-to-date 2025.
Cash receipts from partners totaled $43.9 million in the first nine months of 2025, including $14.3 million from royalties during the third quarter.
The company completed acquisitions of Turnstone Biologics and HilleVax, and announced plans to acquire LAVA Therapeutics and Mural Oncology.
Key pipeline advancements include Zevra Therapeutics' Marketing Authorization Application (MAA) submission for arimoclomol, Rezolute Bio's anticipated December topline data for ersodetug, and Gossamer Bio's expected February 2026 topline results for seralutunib.
Year-to-date 2025, XOMA Royalty deployed $25.0 million to acquire additional assets and repurchased approximately 108,510 shares of its common stock for $2.4 million.

Nov 12, 2025, 12:46 PM

XOMA Royalty Corp Enters into Two "At-The-Market" Equity Offering Agreements

XOMA

New Projects/Investments

XOMA Royalty Corporation entered into a Common Stock Sales Agreement with Leerink Partners LLC on October 3, 2025.
This agreement allows the company to offer and sell up to $75,000,000 of its common stock through Leerink.
The net proceeds from the common stock offering are intended for acquiring additional potential royalty and milestone revenue streams, working capital, and other general corporate purposes.
Leerink Partners LLC will receive a commission of up to 3.0% of the gross proceeds from the common stock sales.
Additionally, XOMA Royalty Corporation entered into an agreement with H.C. Wainwright & Co., LLC to issue and sell Depositary Shares, each representing 1/1000th of a share of 8.375% Series B Cumulative Perpetual Preferred Stock.

Oct 3, 2025, 9:24 PM

XOMA Royalty Corporation Completes Acquisition of HilleVax, Inc.

XOMA

M&A

Takeover Bid

XOMA Royalty Corporation completed the acquisition of HilleVax, Inc. on September 17, 2025, resulting in HilleVax becoming a wholly owned subsidiary of XOMA.
The acquisition was structured as a cash tender offer for HilleVax common stock at $1.95 per share, along with one contingent value right (CVR) per share.
The $1.95 Cash Amount per share was based on an estimated Closing Net Cash of $102,950,000 for HilleVax as of August 4, 2025.
Holders of HilleVax's outstanding common stock, restricted stock unit awards, and in-the-money options received CVRs, which represent the right to receive potential future payments.